Purchase this article with an account.
Ju Byung Chae, Moses Kim, Sungmin Hyung; Assessment of Metamorphopsia in Patients with Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):257.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the presence and extent of metamorphopsia using M-CHARTSTM (Inami Co., Tokyo, Japan) in patients with central serous chorioretinopathy (CSC).
We examined 33 eyes of 33 consecutive CSC patients using M-CHARTS, which yields scores reflecting the severity of metamorphopsia. The condition was considered present when an M-CHARTS score was 0.3 or over. In all patients, optical coherence tomography (OCT) was performed, best-corrected visual acuity (BCVA) was assessed, and M-CHARTS scores were calculated at the first and the 1- and 3-month follow-up visits. The correlation between M-CHARTS scores and BCVA values was determined. We also sought to define relationships between the level of metamorphopsia and specific OCT findings.
Of 33 CSC patients, 15 showed symptoms of metamorphopsia, and all 15 had M-CHARTS scores of over 0.3. However, no correlation was evident between BCVA values and the extent of metamorphopsia as determined using M-CHARTS. In metamorphopsia patients, the incidence of focal retinal pigment epithelial detachment (PED) was notably greater than in the non-metamorphopsia group (p=0.03).
M-CHARTS is valuable for monitoring subjective symptom improvement during the clinical course of CSC. M-CHARTS serves as a useful adjunct to OCT.
This PDF is available to Subscribers Only